作者: Bernard Weber , Anja Bayer , Peter Kirch , Volker Schlüter , Dietmar Schlieper
DOI: 10.1128/JCM.37.8.2639-2647.1999
关键词:
摘要: The performance of hepatitis B virus (HBV) surface antigen (HBsAg) screening assays is continuously improved in order to reduce the residual risk transfusion-associated B. In a multicenter study, new automated rapid assay, Elecsys HBsAg (Roche Diagnostics), was compared well-established tests (Auszyme Monoclonal [overnight incubation] version and IMx [Abbott]). Included evaluation were 23 seroconversion panels; sera from acute chronic phases infection; dilution series various standards, HBV subtypes, S gene mutants; isolated anti-HBV core antigen-positive samples. To challenge specificity HBsAg-negative blood donors, pregnant women, dialysis hospitalized patients potentially cross-reactive samples investigated. showed higher sensitivity for subtypes ad, ay, adw2, adw4, ayw1, ayw2, ayw4, adr detection different standards or than Auszyme and/or HBsAg. Acute detected 11 16 panels between 2 days earlier with alternative assays. mutants equal sensitivity. 100%. had 99.9% specificity, its 96.6%. poorer other conclusion, permits By using highly sensitive assays, low-level carriers among individuals can be detected.